Chemotherapy induced alopecia in breast cancer patients: A monocentric prospective study.

Breast disease Pub Date : 2024-01-01 DOI:10.3233/BD-240019

Wala Ben Kridis, Olfa Boudawara, Afef Khanfir

{"title":"Chemotherapy induced alopecia in breast cancer patients: A monocentric prospective study.","authors":"Wala Ben Kridis, Olfa Boudawara, Afef Khanfir","doi":"10.3233/BD-240019","DOIUrl":null,"url":null,"abstract":"Introduction: Alopecia is one of the main adverse events of chemotherapy in breast cancer. However, its impact is often ignored and underestimated by clinicians. Our aim was to evaluate the quality of life of breast cancer patients with chemotherapy induced alopecia.Methods: We conducted a prospective study including 72 breast cancer patients who developed alopecia on or after stopping chemotherapy in the last 6 months. Clinical information and characteristics of alopecia were assessed using a self-prepared questionnaire. DLQI score was used to evaluate patients' quality of life.Results: We interviewed a total of 72 women with a mean age of 53.5 ± 6 years. Alopecia appeared soon after the first course in 62.5%. All patients actively tried to hide induced hair fall (either by a hat in 6.9% or by a headscarf in 93.1%). Quality of life was impacted in 97.2% of patients with a median DLQI score of 6.5. Women who did not underwent mastectomy were significantly more bothered by hair loss than those who had radical surgery (78.1% vs 55%, p = 0.04). Working status was a significant predictor factor of a bad quality of life due to alopecia (100% in working women vs 58.3% in homemaker or retired patients, p = 0.006).Conclusion: Chemotherapy induced alopecia had a negative impact on quality of life of patients with breast cancer, especially in working women and those who did not have radical surgery. Prior wearing of headscarves did not impact significantly the DLQI score.","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11380241/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/BD-240019","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Alopecia is one of the main adverse events of chemotherapy in breast cancer. However, its impact is often ignored and underestimated by clinicians. Our aim was to evaluate the quality of life of breast cancer patients with chemotherapy induced alopecia.

Methods: We conducted a prospective study including 72 breast cancer patients who developed alopecia on or after stopping chemotherapy in the last 6 months. Clinical information and characteristics of alopecia were assessed using a self-prepared questionnaire. DLQI score was used to evaluate patients' quality of life.

Results: We interviewed a total of 72 women with a mean age of 53.5 ± 6 years. Alopecia appeared soon after the first course in 62.5%. All patients actively tried to hide induced hair fall (either by a hat in 6.9% or by a headscarf in 93.1%). Quality of life was impacted in 97.2% of patients with a median DLQI score of 6.5. Women who did not underwent mastectomy were significantly more bothered by hair loss than those who had radical surgery (78.1% vs 55%, p = 0.04). Working status was a significant predictor factor of a bad quality of life due to alopecia (100% in working women vs 58.3% in homemaker or retired patients, p = 0.006).

Conclusion: Chemotherapy induced alopecia had a negative impact on quality of life of patients with breast cancer, especially in working women and those who did not have radical surgery. Prior wearing of headscarves did not impact significantly the DLQI score.

查看原文本刊更多论文

乳腺癌患者化疗诱发的脱发：单中心前瞻性研究

简介脱发是乳腺癌化疗的主要不良反应之一。然而，临床医生往往忽视或低估其影响。我们的目的是评估化疗引起脱发的乳腺癌患者的生活质量：我们开展了一项前瞻性研究，纳入了 72 名在过去 6 个月中停止化疗或化疗后出现脱发的乳腺癌患者。我们使用自拟的问卷对脱发的临床信息和特征进行了评估。DLQI评分用于评估患者的生活质量：我们共访问了 72 名女性患者，她们的平均年龄为 53.5 ± 6 岁。62.5%的患者在首次治疗后不久出现脱发。所有患者都试图掩盖引起的脱发（6.9%的患者戴帽子，93.1%的患者戴头巾）。97.2%的患者生活质量受到影响，DLQI中位数为6.5分。未接受乳房切除术的女性受脱发困扰的比例明显高于接受根治性手术的女性（78.1% 对 55%，P = 0.04）。工作状况是脱发导致生活质量下降的一个重要预测因素（职业女性为100%，家庭主妇或退休患者为58.3%，P = 0.006）：化疗引起的脱发对乳腺癌患者的生活质量有负面影响，尤其是职业女性和未接受根治性手术的患者。曾戴头巾对 DLQI 评分没有明显影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast disease Medicine-Oncology

CiteScore

1.80

自引率

0.00%

发文量

期刊介绍： The recent expansion of work in the field of breast cancer inevitably will hasten discoveries that will have impact on patient outcome. The breadth of this research that spans basic science, clinical medicine, epidemiology, and public policy poses difficulties for investigators. Not only is it necessary to be facile in comprehending ideas from many disciplines, but also important to understand the public implications of these discoveries. Breast Disease publishes review issues devoted to an in-depth analysis of the scientific and public implications of recent research on a specific problem in breast cancer. Thus, the reviews will not only discuss recent discoveries but will also reflect on their impact in breast cancer research or clinical management.